TABLE 2.

Identification of novel SHIV epitopesa

PeptideSequencebReactive time point(s)c (wk)
EVGP/DMGPE/DMGPE/3M
Env 336-355 gp120 C3RAKWNNTLQQIVIKLREKFR27
Env 621-640 gp41 C-helixWNNMTWMEWEREIDNYTDYI+20+2
Env 701-720 gp41 MPISIVNRVRQGySPLSFQTLLP+8
Env 746-765 gp41 C terminus*VNGFLALFWVDLRNLCLFLY+22+8+2, +9, +22
Env 756-775 gp41 C terminusDLRNLCLFLYHLLRNLLLIV+9
Gag 452-473 p6VHQGLMPTAPPEDPAVDLLKNY+22+22
Gag 461-480 p6PPEDPAVDLLKNYMQLGKQQ+22+22
Gag 472-493 p6*NYMQLGKQQREKQRESREKPYK+22+9, +2049, +9, +20
Gag 482-503 p6EKQRESREKPYKEVTEDLLHLN+22+9, +20
Gag 491-510 p6PYKEVTEDLLHLNSLFGGDQ+22+2, +20
Gag 492-510 p6*YKEVTEDLLHLNSLFGGDQ+22+2, +9, +20+9, +20
Pol 031-050 N terminusLQVWGRDNNSPSEAGADRQG+9
Pol 271-290 RTFSVPLDEDFRKYTAFTIPSI+9+2
Pol 281-300 RTKYTAFTIPSINNETPGIRYQ27
Pol 541-560 RTTPKFKLPIQKETWETWWTEY+2
Pol 621-640 RNaseVVTLTDTTNQKTELQAIYLA+2
Tat 025-039CYCKKCCFHCQACFI+2, +9
Tat 089-100KVERETETDPVH2727
  • a Peptides from regions of SHIV proteins that have statically significant antibody reactivity but do not overlap epitopes previously described are shown with the experimental groups and time points at which their reactivities were detected. Peptides marked with asterisks were detected in at least three of the test groups and at more than one time point and thus appear to represent consistent targets for antiviral B-cell responses.

  • b Lowercase y in Env 701 indicates a tyrosine residue that was mutated to cysteine in the DNA vaccine. Underlined residues were deleted from Env in the rMVA vaccine.

  • c Time points 27 and 49 refer to weeks after initial vaccination; time points +2, +8, +9, +20, and +22 refer to weeks after SHIV challenge. See the legend to Fig. 4 for definitions of groups.